Pancreatic Neuroendocrine Tumors Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Novartis Pharmaceuticals, Pfizer, Keyrus Biopharma, Merck Sharp & Dohme LLC, Pfizer, Apices Soluciones S.L., Pharmacycl

DelveInsight's "Pancreatic Neuroendocrine Tumors Drugs Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Pancreatic Neuroendocrine Tumors, historical and forecasted epidemiology as well as the Pancreatic Neuroendocrine Tumors market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Discover which therapies are expected to grab the Pancreatic Neuroendocrine Tumors Market Share @ Pancreatic Neuroendocrine Tumors Market Outlook- https://www.delveinsight.com/sample-request/pancreatic-neuroendocrine-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Pancreatic Neuroendocrine Tumors Market Report
• In January 2025, Elicera Therapeutics received FDA Orphan Drug Designation for its drug candidate ELC-100, aimed at treating pancreatic neuroendocrine tumors, highlighting its potential as a promising therapy for this challenging cancer.
• 'GEP-NETs represent the second most common digestive cancer in terms of prevalence.
• According to findings, small intestine (30.8%), (26.3%), colon (17.6%), pancreas (12.1%), and appendix (5.7%) are the most common primary NET sites in the digestive tract.
• The old age population is more susceptible to suffering from Pancreatic Neuroendocrine Tumors.
• The leading Pancreatic Neuroendocrine Tumors Companies such as Novartis Pharmaceuticals, Pfizer, Keyrus Biopharma, Merck Sharp & Dohme LLC, Pfizer, Apices Soluciones S.L., Pharmacyclics LLC., IPSEN, and others.
• Promising Pancreatic Neuroendocrine Tumors Pipeline Therapies such as LUTATHERA, WELIREG, and others.

Stay ahead in the Pancreatic Neuroendocrine Tumors Therapeutics Market with DelveInsight's Strategic Report @ Pancreatic Neuroendocrine Tumors Market Outlook- https://www.delveinsight.com/sample-request/pancreatic-neuroendocrine-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pancreatic Neuroendocrine Tumors Epidemiology
• Total Pancreatic Neuroendocrine Tumors Incident Cases
• Pancreatic Neuroendocrine Tumors Subtype-specific Cases
• Pancreatic Neuroendocrine Tumors Symptom-based Incidence
• Pancreatic Neuroendocrine Tumors Stage-wise Cases
• Pancreatic Neuroendocrine Tumors Grade-wise Cases
• Pancreatic Neuroendocrine Tumors Gender-specific Cases

Download the report to understand which factors are driving Pancreatic Neuroendocrine Tumors Epidemiology trends @ Pancreatic Neuroendocrine Tumors Prevalence- https://www.delveinsight.com/sample-request/pancreatic-neuroendocrine-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pancreatic Neuroendocrine Tumors Marketed Drugs
• LUTATHERA: Novartis
Lutathera (lutetium Lu 177 dotatate*) is a lutetium Lu 177-labeled somatostatin analog peptide. Lutathera belongs to a class of treatments called Peptide Receptor Radionuclide Therapy (PRRT). Lutathera is comprised of a targeting molecule that carries a radioactive component. Lutathera has received orphan drug designation from the FDA and the European Medicines Agency (EMA). It was approved in 2018 by the US FDA for the treatment of adult patients with SSTR-positive GEP-NETs, including those in the foregut, midgut, and hindgut. Lutathera is also approved in Europe for unrespectable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptors (SSTR)-positive GEP-NETs in adults, and in Japan for SSTR-positive NETs.

Pancreatic Neuroendocrine Tumors Emerging Drugs
• ITM-11: ITM Isotope Technologies Munich
ITM-11 (177Lu-edotreotide), being developed by ITM Isotope Technologies Munich, is an innovative Targeted Radionuclide Therapy agent consisting of two components: firstly, Edotreotide (DOTATOC), an octreotide-derived somatostatin analog, and secondly, EndolucinBeta (no-carrier-added (n.c.a.) lutetium-177 chloride) a synthetic, low-energy beta-emitting therapeutic radioisotope. It is currently being investigated in two Phase III clinical trials, COMPETE (NCT03049189) and COMPOSE (NCT04919226). While COMPETE is evaluating ITM-11 for the treatment of patients with grade 1 and grade 2 GEP-NETs, the radiopharmaceutical candidate is also being investigated in COMPOSE, for patients with well-differentiated high grade 2 and grade 3 GEP-NETs. ITM-11 received an orphan designation as a treatment for GEP-NETs based on the data from a Phase II clinical study, which demonstrated a significant benefit (substantially improved progression-free survival, PFS).

• WELIREG (MK-6482): Merck
Belzutifan (MK-6482) is a novel, potent and selective inhibitor of HIF-2α. Proteins known as hypoxia-inducible factors, including HIF-2α, can accumulate in patients when VHL, a tumor-suppressor protein, is inactivated. If not properly regulated, the accumulation of HIF-2α can stimulate several oncogenes associated with cellular proliferation, angiogenesis, and tumor growth, leading to the growth of both benign and malignant tumors. Currently, it is in Phase II of its clinical development for the treatment of Pancreatic Neuroendocrine Tumors.

To learn more about Pancreatic Neuroendocrine Tumors treatment guidelines, visit @ Pancreatic Neuroendocrine Tumors Treatment Market Landscape- https://www.delveinsight.com/sample-request/pancreatic-neuroendocrine-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pancreatic Neuroendocrine Tumors Market Outlook
The report's outlook on the Pancreatic Neuroendocrine Tumors market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Pancreatic Neuroendocrine Tumors therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Pancreatic Neuroendocrine Tumors drug and late-stage pipeline therapy.

Pancreatic Neuroendocrine Tumors Drugs Uptake
The drug chapter of the Pancreatic Neuroendocrine Tumors report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Pancreatic Neuroendocrine Tumors.

Major Pancreatic Neuroendocrine Tumors Companies
Novartis Pharmaceuticals, Pfizer, Keyrus Biopharma, Merck Sharp & Dohme LLC, Pfizer, Apices Soluciones S.L., Pharmacyclics LLC., IPSEN, and others.

Learn more about the FDA-approved drugs for Pancreatic Neuroendocrine Tumors @ Drugs for Pancreatic Neuroendocrine Tumors Treatment- https://www.delveinsight.com/sample-request/pancreatic-neuroendocrine-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Pancreatic Neuroendocrine Tumors Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Pancreatic Neuroendocrine Tumors Companies- Novartis Pharmaceuticals, Pfizer, Keyrus Biopharma, Merck Sharp & Dohme LLC, Pfizer, Apices Soluciones S.L., Pharmacyclics LLC., IPSEN, and others.
• Pancreatic Neuroendocrine Tumors Pipeline Therapies- LUTATHERA, WELIREG, and others.
• Pancreatic Neuroendocrine Tumors Market Dynamics: Pancreatic Neuroendocrine Tumors Market Drivers and Barriers
• Pancreatic Neuroendocrine Tumors Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Pancreatic Neuroendocrine Tumors Drugs in development @ Pancreatic Neuroendocrine Tumors Clinical Trials Assessment- https://www.delveinsight.com/sample-request/pancreatic-neuroendocrine-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1: Key Insights
2: Pancreatic Neuroendocrine Tumors Market Overview at a Glance (7MM)
3: Disease Background and Overview: Pancreatic Neuroendocrine Tumors (PNET)
4: Management of Neuroendocrine Tumors: Diagnostic Recommendations
5: Epidemiology and Patient Population
6: Country Wise-Epidemiology of PNET
7: Treatment Practices
8: Unmet Needs
9: Marketed Products
10: Emerging Candidates
11: Pancreatic Neuroendocrine Tumors [PNET] Market Analysis: 7MM
12: Appendix
13: Report Methodology
14.1: Sources Used
15: DelveInsight Capabilities
16: Disclaimer
17: About DelveInsight

List of Top Selling Market Research Reports in 2025

NK Cell Therapy Market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Psoriasis Vulgaris Market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
Surgical Energy Instruments Market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Urea Cycle Disorders Market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Immune Checkpoints Activators Market- https://www.delveinsight.com/report-store/immune-checkpoint-inhibitors-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Cystic Fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Surgical Robotic System Market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market
Diabetic Wound Market- https://www.delveinsight.com/report-store/diabetic-wounds-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Overactive Bladder Syndrome Market- https://www.delveinsight.com/report-store/underactive-bladder-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Healthcare Competitive Benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Intraocular Lens Market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/blog/cardiac-monitoring-devices-market
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Surgical Mask & Respirator Market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Total Knee Arthroplasty Market - https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Bone Growth Stimulator Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.